Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial

The Lancet Oncology

Volumn 16, Issue 9, 2015, Pages 1090-1098

  Shapiro, Joel ^a   van Lanschot, J Jan B ^a,b   Hulshof, Maarten C C M ^b   van Hagen, Pieter ^a   van Berge Henegouwen, Mark I ^b   Wijnhoven, Bas P L ^a   van Laarhoven, Hanneke W M ^b   Nieuwenhuijzen, Grard A P ^c   Hospers, Geke A P ^d   Bonenkamp, Johannes J ^e   Cuesta, Miguel A ^f   Blaisse, Reinoud J B ^g   Busch, Olivier R C ^b   ten Kate, Fiebo J W ^a,b   Creemers, Geert Jan M ^c   Punt, Cornelis J A ^b,e   Plukker, John Th M ^d   Verheul, Henk M W ^f   Bilgen, Ernst J Spillenaar ^g   van Dekken, Herman ^a,h   van der Sangen, Maurice J C ^c   Rozema, Tom ^e,i   Biermann, Katharina ^a   Beukema, Jannet C ^d   Piet, Anna H M ^f   van Rij, Caroline M ^a   Reinders, Janny G ^j   Tilanus, Hugo W ^a   Steyerberg, Ewout W ^a   van der Gaast, Ate ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^j Arnhems Radiotherapeutisch Instituut   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LENGTH OF STAY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NETHERLANDS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; KAPLAN MEIER METHOD; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; PATHOLOGY; RADIATION RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 84940595393     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00040-6     Document Type: Article

References (22)

1. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662-1669.
2. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719-3725.
3. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
5. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29:1715-1721.
6. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226-234.
7. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681-692.
8. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
9. van Heijl M, van Lanschot JJB, Koppert LB, et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008, 8:21.
10. Sobin LH, Wittekind C, et al. TNM classification of malignant tumors 2002, Wiley-Liss, New York. 6th edn.
11. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25:2127-2132.
12. Fumagalli D, Bedard PL, Nahleh Z, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 2012, 13:e240-e248.
13. Altman DG, Andersen PK Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999, 319:1492-1495.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
15. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA Evaluating the yield of medical tests. JAMA 1982, 247:2543-2546.
16. Grambsch PM, Therneau TM Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
17. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851-856.
18. Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011, 47:354-360.
19. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
20. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006, 24:2743-2749.
21. Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 2013, 43:752-755.
22. Keegan N, Keane F, Cuffe S, Cunningham M, Ravi N, Lee G ICORG 10-14: Neo-AEGIS: a randomized clinical trial of neoadjuvant and adjuvant chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction. Proc Am Soc Clin Oncol 2014, 32(5 suppl). abstr TPS4145.